MedTrace Logo

Genotype Information and Functional Testing Study

NCT00992420 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 2000

Last updated 2022-11-23

No results posted yet for this study

Summary

This study is a sub-study of GRAVITAS (clinicaltrials.gov identifier NCT00645918). The purpose of this study is to assess which genes influence residual platelet reactivity on standard dose clopidogrel therapy, and also to determine whether certain genes influence the incremental change in platelet reactivity with high-dose clopidogrel maintenance dosing in patients who have high residual platelet reactivity on standard dosing.

Conditions

Sponsors & Collaborators

  • Bristol-Myers Squibb

    collaborator INDUSTRY

  • Sanofi

    collaborator INDUSTRY

  • Accumetrics, Inc.

    collaborator INDUSTRY

  • Scripps Health

    lead OTHER

Principal Investigators

  • Matthew J Price, MD · Scripps Clinic, La Jolla, CA

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-10-01
Primary Completion
2010-08-31
Completion
2010-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00992420 on ClinicalTrials.gov